TY  - JOUR
AU  - Van-Wijmeersch, Bart
AU  - Singer, Barry A
AU  - Boster, Aaron
AU  - Broadley, Simon
AU  - Fernandez, Oscar
AU  - Freedman, Mark S
AU  - Izquierdo, Guillermo
AU  - Lycke, Jan
AU  - Pozzilli, Carlo
AU  - Sharrack, Basil
AU  - Steingo, Brian
AU  - Wiendl, Heinz
AU  - Wray, Sibyl
AU  - Ziemssen, Tjalf
AU  - Chung, Luke
AU  - Margolin, David H
AU  - Thangavelu, Karthinathan
AU  - Vermersch, Patrick
PY  - 2019
DO  - 10.1177/1352458519881759
UR  - http://hdl.handle.net/10668/14618
T2  - Multiple sclerosis (Houndmills, Basingstoke, England)
AB  - Alemtuzumab is administered as two annual courses for relapsing-remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen. The objective was to evaluate 6-year outcomes in patients who relapsed between...
LA  - en
PB  - Sage Publications
KW  - Alemtuzumab
KW  - Disability
KW  - Disease-modifying therapy
KW  - Efficacy
KW  - Magnetic resonance imaging (MRI)
KW  - Relapsing–remitting multiple sclerosis (MS)
KW  - Alemtuzumab
KW  - Antibodies, Monoclonal, Humanized
KW  - Humans
KW  - Interferon beta-1a
KW  - Multiple Sclerosis
KW  - Multiple Sclerosis, Relapsing-Remitting
TI  - Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
TY  - research article
VL  - 26
ER  -